[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 375
Citations 0
Observation
October 2016

Treatment of Generalized Deep Morphea With Everolimus

Author Affiliations
  • 1Dermatology Department, Saint-Louis Hospital, Paris, France
  • 2Paris VII Sorbonne Paris Cité University, Paris, France
JAMA Dermatol. 2016;152(10):1170-1172. doi:10.1001/jamadermatol.2016.2338

Localized scleroderma, or morphea, is a chronic inflammatory disease that involves skin and subcutaneous tissues, causing skin sclerosis. Several classifications have been published including those of Laxer and Zulian1: circumscribed, linear, generalized, pansclerotic, or mixed. In contrast to systemic sclerosis, morphea does not involve internal organs. Generalized morphea (GM) is a form of severe morphea with substantial effect on quality of life and survival. First-line systemic treatments for severe morphea include phototherapy, systemic steroids, and methotrexate. Data regarding therapeutic management of GM are scarce, limited to case reports and small case series. We describe a case of GM that was successfully treated with everolimus, an mTOR (mechanistic target of rapamycin) inhibitor.

First Page Preview View Large
First page PDF preview
First page PDF preview
×